Abstract

A NOVEL FORMULATION AGAINST DIABETES-INDUCED NEUROBEHAVIOURAL IMPAIRMENTS AND NEURODEGENERATIVE DISORDER IN IN VIVO EXPERIMENTAL MODELS

Rituraj Tripathi*, Lavakesh Kumar Omray, Naveen Gupta and Dharmendra Singh Rajput

.

Abstract

Background: Diabetes is associated with neurobehavioural impairments and an increased risk of neurodegenerative disorders. Current treatments provide limited efficacy, highlighting the need for novel therapeutic approaches. Objective: This study evaluates the neuroprotective effects of a novel formulation against diabetes-induced neurobehavioural impairments and neurodegenerative changes in in vivo experimental models. Methods: Male Wistar rats were divided into four groups: control, diabetic, diabetic treated with a standard drug, and diabetic treated with the novel formulation. Diabetes was induced using streptozotocin (STZ, 60 mg/kg, i.p.). Behavioral assessments included the Morris Water Maze (MWM) for cognitive function, the Open Field Test (OFT) for anxiety-like behavior, and the Rotarod test for motor coordination. Histopathological and immunohistochemical analyses were performed to assess neurodegenerative changes. Results: In the MWM test, diabetic rats showed a 70% increase in escape latency compared to controls, while the novel formulation group demonstrated a 65% reduction in latency, indicating improved spatial memory. The OFT revealed a 50% reduction in locomotor activity in diabetic rats, which was significantly restored (80% of control levels) by the novel formulation. Rotarod performance in diabetic rats declined by 60%, but treatment with the novel formulation improved performance by 70%. Histological analysis showed severe neuronal loss in diabetic rats, which was significantly mitigated by the novel formulation. Immunohistochemistry revealed a 75% reduction in Aβ and tau protein expression in the novel formulation group compared to diabetic rats. Conclusion: The novel formulation significantly ameliorated diabetes-induced neurobehavioural impairments and neurodegenerative changes, suggesting its potential as a therapeutic agent for diabetes-associated neurological complications. Further studies are required to confirm these findings and explore its clinical applicability.

Keywords: .